Shapiro Nathan I, Howell Michael, Talmor Daniel
Beth Israel Deaconess Medical Center, 1 Deaconess Road, CC2-W, Boston, MA 02215, USA.
Acad Emerg Med. 2005 Apr;12(4):352-9. doi: 10.1197/j.aem.2004.11.017.
Despite numerous advances in medicine, sepsis remains an unconquered challenge. Although outcomes have improved slightly over decades, the unacceptably high mortality rate of 30%-50% for severe sepsis and septic shock continues. However, after years of unsuccessful clinical trials, several investigations over the last few years have reported survival benefit in the treatment of sepsis. Physicians now have several proven therapies to treat sepsis, but have yet to implement them on a widespread, systematic basis. This led 11 international professional societies spanning multiple specialties and continents to come together to create the Surviving Sepsis Campaign. The product of their work is an international effort organized to improve care of patients with sepsis and includes consensus, evidence-based guidelines for care that improves survival in septic patients, and an action plan for change. Given the clear role of early identification and treatment in stopping the sepsis cascade, therapy must start early in the emergency department (ED) and continue throughout the hospital course. The first of the recommendations by the Surviving Sepsis Campaign is the aggressive resuscitation strategy of early goal-directed therapy (EGDT). EGDT is reported to reduce absolute mortality by a staggering 16%. The use of recombinant activated protein C was demonstrated to confer a 6% absolute survival benefit. Steroid supplementation in adrenal insufficiency produced a 10% benefit. Additionally, early and appropriate use of antibiotics remains a cornerstone of therapy. Although no randomized trial will be performed, the effects are undisputed. Finally, although predominantly intensive care unit therapies, tight glucose control and low-tidal-volume ventilation strategies have also led to improved survival. Armed with these new therapies, the medical community must rise to this call to action. Clinicians must change the approach to this disease, as well as the way the septic patient is viewed. Although complex and challenging, these therapies must be brought to the patient's bedside. We propose and describe the Multiple Urgent Sepsis Therapies (MUST) protocol as a practical way to implement a comprehensive treatment plan using available evidence-based therapies.
尽管医学取得了诸多进展,但脓毒症仍然是一个尚未攻克的挑战。虽然几十年来治疗结果略有改善,但严重脓毒症和脓毒性休克高达30%-50%的死亡率仍令人难以接受。然而,经过多年临床试验未取得成功后,过去几年的多项研究报告了脓毒症治疗中的生存获益。医生现在有几种已证实的治疗脓毒症的方法,但尚未在广泛、系统的基础上实施。这促使来自多个专业领域和各大洲的11个国际专业学会联合起来发起了拯救脓毒症运动。他们工作的成果是一项旨在改善脓毒症患者护理的国际行动,包括关于改善脓毒症患者生存的护理的共识性、循证指南以及变革行动计划。鉴于早期识别和治疗在阻止脓毒症级联反应中的明确作用,治疗必须在急诊科尽早开始,并贯穿整个住院过程。拯救脓毒症运动的首要建议是早期目标导向治疗(EGDT)的积极复苏策略。据报道,EGDT可使绝对死亡率惊人地降低16%。使用重组活化蛋白C可带来6%的绝对生存获益。肾上腺功能不全时补充类固醇可带来10%的获益。此外,早期和适当使用抗生素仍然是治疗的基石。尽管不会进行随机试验,但其效果是无可争议的。最后,尽管主要是重症监护病房的治疗方法,但严格血糖控制和低潮气量通气策略也已带来生存改善。有了这些新疗法,医学界必须响应这一行动号召。临床医生必须改变对这种疾病的治疗方法以及看待脓毒症患者的方式。尽管这些疗法复杂且具有挑战性,但必须将其应用到患者床边。我们提出并描述了多重紧急脓毒症治疗(MUST)方案,作为一种使用现有循证疗法实施全面治疗计划的实用方法。